Abstract
Background: Human rhinovirus (HRV) and human metapneumovirus (hMPV) are common viral causes of pediatric respiratory tract infections. Bacterial co-infections frequently complicate these illnesses, but their impact on disease severity is not well understood. Objectives: This study aimed to compare the clinical features of HRV and hMPV mono-infections and assess the impact of bacterial co-infection on disease severity. Methods: A retrospective analytical cross-sectional study was conducted on hospitalized children (≤ 14 years) in 2022. Results: hMPV mono-infection generally exhibited more severe symptoms (fever, cough, pneumonia) than HRV, except in children ≥ 6 years. For HRV, bacterial co-infection significantly increased pneumonia rates, PICU admissions, and hospitalization length. No such significant difference was found for hMPV. Conclusions: hMPV mono-infection is inherently more severe than HRV mono-infection, but bacterial co-infection acts as a significant exacerbator for HRV infections.
Introduction
Acute respiratory infections (ARIs) remain a leading cause of pediatric hospitalization globally. While Human Rhinovirus (HRV) and Human Metapneumovirus (hMPV) are frequently identified, they are often treated similarly in clinical settings. However, understanding the distinct "clinical signatures" of these viruses and how they interact with secondary bacterial pathogens is critical for optimizing treatment strategies, such as the timely initiation of antibiotics or escalation of care. This study provides a data-driven comparison of these two viral pathogens and evaluates the impact of bacterial co-infection on clinical outcomes.
Methods
This retrospective study analyzed data from the Maternal and Child Health Hospital of Hubei Province in Wuhan, China, throughout 2022. The study included 1,978 children hospitalized with HRV and 1,117 with hMPV. Viral detection was performed using PCR capillary electrophoresis on nasopharyngeal secretions or alveolar lavage fluid. Bacterial co-infections were identified through cultures from sterile or non-sterile sites, with species identification via MALDI-TOF mass spectrometry. Researchers compared mono-infections against co-infections across demographics, clinical symptoms (fever, wheezing, rales), and outcomes (PICU admission, length of stay).
Results
HRV vs. hMPV Mono-infections
The study found that hMPV is generally the "heavier hitter" compared to HRV. Even as a mono-infection, hMPV was associated with higher rates of fever, cough, and pneumonia, particularly in children under six years old. Conversely, HRV was more frequently associated with wheezing, suggesting a different physiological impact on pediatric airways.
The Impact of Bacterial Co-infection
A key finding was the disparity in how bacterial co-infection affected each virus. For HRV, the presence of bacteria significantly worsened clinical outcomes. Co-infected children had a higher proportion of pneumonia (76.2% vs. 50.8%), increased PICU admissions (12.7% vs. 3.1%), and longer hospitalizations (6.24 vs. 4.93 days) compared to those with HRV mono-infection ($P < 0.05$).
In contrast, bacterial co-infection did not significantly alter the clinical course of hMPV infections. This suggests that hMPV may be inherently cytotoxic enough that additional bacterial damage does not statistically change the overall severity of the disease. Streptococcus pneumoniae was the most common bacterial co-pathogen identified in both groups.
Discussion and Conclusion
The study highlights that while hMPV mono-infections are typically more severe than HRV mono-infections, bacterial co-infection acts as a significant "force multiplier" for HRV. This synergy drastically worsens outcomes for HRV patients, whereas hMPV's high baseline pathogenicity appears to mask the impact of secondary bacterial infections.
Limitations of the study include its retrospective design and the potential for underestimated co-infection rates due to pre-hospitalization antibiotic use. Furthermore, the 2022 timeframe reflects a period of unique social distancing measures. Future prospective research is needed to explore the molecular mechanisms of these viral-bacterial interactions and determine if specific bacterial strains are more likely to drive severe outcomes in viral ARIs. In conclusion, clinicians should be particularly vigilant for bacterial co-infection in HRV cases, as it significantly escalates disease severity.
Summary updated